Email this article Cytological method of diagnostics of pleural effusion using immunocytochemical and molecular genetic techniques
- Authors: Grigoruk O.G.1,2, Pupkova Е.Е.2, Bazulina L.M.2
-
Affiliations:
- Altai Regional Oncological Dispensary
- The Altai State Medical University
- Issue: Vol 25, No 3 (2020)
- Pages: 82-91
- Section: Original Study Articles
- URL: https://rjonco.com/1028-9984/article/view/47089
- DOI: https://doi.org/10.17816/1028-9984-2020-25-3-82-91
- ID: 47089
Cite item
Open Access
Access granted
Abstract
The aim of the study is to estimate the potentiality of using immunocytochemical and molecular genetic techniques in diagnosis of patients with pleural effusion. Materials and methods. The results of a cytological study of 580 patients with pleural effusion examined in the Altai Regional Oncological Dispensary in 2019 were evaluated. Immunocytochemical and molecular genetic techniques were applied using cytological specimens prepared from pleural fluid. Epidermal growth factor receptor (EGFR) gene status was determined. Results. Non-tumor pleural effusion was diagnosed in 378 cases (65%). Tumorous cells of 181 (31%) patients were found in pleural effusion. It was very difficult to diagnose a pathological process by cell composition in 21 (4%) cases because of the inability to distinguish histiocytes and mesothelial cells from tumor cells using light microscopy. Immunocytochemical researches of 105 patients with pleural effusion were used for specification of metastases and in uncertain diagnostic cases. EGFR gene mutation for the diagnosed pulmonary adenocarcinoma had been determined in 31 cases for proper assignment of the target medicines. Dotty L858R mutation and deletions 19 exon were detected. Conclusions: Light microscopy allowed us to differentiate tumor and non-tumor plural effusion in 96% of cases. Immunocytochemical technique revealed the primary tumor site in 95% of cases of pleural effusions. Cytological specimens are full-advantaged material for molecular genetic technique. Mutations were found in 19% of cases.
Full Text
About the authors
Olga G. Grigoruk
Altai Regional Oncological Dispensary; The Altai State Medical University
Author for correspondence.
Email: cytolakod@rambler.ru
ORCID iD: 0000-0001-9981-2348
the Head of the Cytological Laboratory of the Altai Regional Oncological Dispensary, Associate Professor of the Department of General and Biological Chemistry, Clinical Laboratory Diagnostics, Altai State Medical University
Russian Federation, BarnaulЕ. Е. Pupkova
The Altai State Medical University
Email: cytolakod@rambler.ru
ORCID iD: 0000-0001-7369-1883
Russian Federation, Barnaul
L. M. Bazulina
The Altai State Medical University
Email: cytolakod@rambler.ru
ORCID iD: 0000-0002-7222-0657
Russian Federation, Barnaul
References
- Rossi E.D., Bizzarro T., Schmitt F., Longatto-Filho A. The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience. Cancer Cytopathol. 2015;123(4):258-66. doi: 10.1002/cncy.21518.
- Lepus C.M., Vivero M. Updates in Effusion Cytology. Surg. Pathol. Clin. 2018;11(3):523-44. doi: 10.1016/j.path.2018.05.003.
- Lee Y.M., Hwang J.Y., Son S.M., Choi S.Y., Lee H.C., Kim E.J., Han H.S., An J.Y., Han J.H., Lee O.J. Comparison of diagnostic accuracy between CellPrepPlus and ThinPrep liquid-based preparations in effusion cytology. Diagn. Cytopathol. 2014;42:384-90. doi: 10.1002/dc.23041.
- Grigoruk O.G., Lazarev A.F., Dudarenko S.V., Shoychet J.N. Differential cytological diagnostics of tumor and non-tumor pleural effusions. [Differentsial’naya tsitologicheskaya diagnostika opukholevyh b neopukholevyh vypotov.] Barnaul: AZBUKA, 2017:68-84. (In Russian)
- Gabriel C., Achten R., Drijkoningen M. Use of liquid based cytology in serous fluids: a comparison with conventional cytopreparatory techniques. Acta Cytol. 2004;48:8258-35. doi: 10.1159/000326453
- Loveland P., Christie M., Hammerschlag G., Irving L., Steinfort D. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience. Intern Med J. 2018 Nov; 48(11):1318-24. doi: 10.1111/imj.13991.
- Karpathiou G., Stefanou D., Froudarakis M.E. Pleural neoplastic pathology. Respir Med. 2015 Aug; 109(8):931-43. doi: 10.1016/j.rmed
- Porcel J.M. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis. 2018;12:1753466618808660. doi: 10.1177/1753466618808660
- Chaini E., Athanassiadou A.M., Vassias A., Tsipis A. et al. Immunocytochemical expression of a panel of markers in pleural effusions from patients with primary lung adenocarcinoma. Pathol Res Pract. 2017 May; 213(5):502-8. doi: 10.1016/j.prp.2017.02.002. Epub 2017 Feb 7.
- Hoda R.S. Non-gynecologic cytology on liquid based cytology preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621-634. doi: 10.1002/dc.20698
- Mok T.S., Wu Y.L., Thongprasert S., Yang C.H. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep;361(10):947-57. doi: 10.1056/NEJMoa0810699.
- Paez J.G., Jänne P.A., Lee J.C., Tracy S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500.
- Aisner D.L., Deshpande C., Baloch Z., Watt C.D. et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol. 2013 Apr; 41(4):316-23. doi: 10.1002/dc.21851.
- Ellison G., Zhu G., Moulis A., Dearden S., Speake G., McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013 Feb; 66(2):79-89. doi: 10.1136/jclinpath-2012-201194.
- Leslie C., Giardina T., Carrello A., Spagnolo D.V., Amanuel B. Detection of EGFR mutational profile by direct dideoxy sequencing in cytology and non-cytology biopsysamples. Pathology. 2014 Jun; 46(4):283-8. doi: 10.1097/PAT.0000000000000093.
- Malapelle U., Bellevicine C., De Luca C., Salatiello M. et al. EGFR mutations detected oncytology samples bya centralized laboratory reliably predict response to gefitinibin non-small cell lung carcinoma patients. Cancer Cytopathol. 2013 Oct; 121(10):552-60. doi: 10.1002/cncy.21322.
- Pang B., Dettmer M., Ong C.W., Dhewar A.N. et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory’s analysis of 670 cases. Cytopathology. 2012 Aug;23(4):229-36. doi: 10.1111/j.1365-2303.2012.01000.x.
- Smouse J.H., Cibas E.S., Jänne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer. 2009 Feb 25;117(1):67-72. doi: 10.1002/cncy.20011.
- Wang S., Yu B., Ng C.C., Mercorella B., Selinger C.I., O’Toole S.A., Cooper W.A. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Transl Lung Cancer Res. 2015 Apr;4(2):119-25. doi: 10.3978/j.issn.2218-6751.2015.01.05.
- Liu L., Shao D., Deng Q., Tang H. et al. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. J Thorac Dis. 2018 May;10(5):2631-7. doi: 10.21037/jtd.2018.04.125.
- Ivantsov A.O., Kleshchev M.A., Ivko J.A. et al. Procssing of morphological material for molecular genetic tests. Voprosy oncology. 2016;62(2):351-4. (In Russian)
- Mityushkina N.V., Ievleva A.G., Poltoratsky A.N. et al. Assessment of applicability of archived cytological lung cancer specimens for molecular genetic analysis. Voprosy oncology. 2015;61(6):968-71. (In Russian)
Supplementary files
